Cognition Therapeutics INC 8-K filings

Cognition Therapeutics announced second quarter 2026 financial results, highlighting progress in its dementia with Lewy bodies program and an extended patent for zervimesine.

Cognition Therapeutics reached FDA alignment on a pivotal Phase 3 trial design for zervimesine to treat psychosis in dementia with Lewy bodies.

Cognition Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders, including the election of two Class II directors and the ratification of its independent auditor.

Cognition Therapeutics presented an update on its investigational oral therapy, zervimesine (CT1812), highlighting its potential for treating psychosis in Dementia with Lewy Bodies (DLB) and its ongoing clinical studies.

Cognition Therapeutics announced a productive meeting with the FDA regarding zervimesine for dementia with Lewy bodies psychosis, discussing a path forward for a registrational program.

Cognition Therapeutics reports Q1 2026 financial results, showing reduced net loss and operating expenses, while preparing for a key FDA meeting regarding zervimesine for DLB psychosis.

Cognition Therapeutics reports year-end 2025 financial results and provides a positive clinical development update, focusing on advancing zervimesine for dementia with Lewy bodies (DLB) psychosis.

Cognition Therapeutics announced plans to advance zervimesine for dementia with Lewy bodies psychosis following positive FDA feedback.

Cognition Therapeutics announced the completion of a productive Type C meeting with the FDA regarding its zervimesine drug for dementia with Lewy bodies.

Cognition Therapeutics, Inc. has entered into a new 'at-the-market' equity offering agreement for up to $75 million, simultaneously terminating its previous $40 million program.

Cognition Therapeutics reported Q3 2025 financial results, secured $30 million in funding, and achieved FDA alignment on a registrational path for its lead Alzheimer's drug, zervimesine.

Cognition Therapeutics reports compelling Phase 2 data for Zervimesine across Alzheimer's, DLB, and dry AMD, advancing it to Phase 3 trials.

Cognition Therapeutics, Inc. announced a registered direct offering of 14.7 million common shares to institutional investors, raising approximately $30.1 million in gross proceeds.

Cognition Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, avoiding potential delisting.

Cognition Therapeutics reports Q2 2025 financial results and significant progress across its Alzheimer's, DLB, and dry AMD clinical programs.

Cognition Therapeutics, Inc. announced the successful election of two Class I directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Cognition Therapeutics, Inc. announced the launch of an expanded access program for its investigational drug zervimesine (CT1812) for patients with dementia with Lewy bodies, substantially funded by an anonymous philanthropic donation.

Cognition Therapeutics, Inc. (CGTX) has reported compelling Phase 2 clinical trial results for its lead candidate, zervimesine (CT1812), demonstrating consistent efficacy signals in Alzheimer's disease, Dementia with Lewy Bodies (DLB), and dry Age-related Macular Degeneration (AMD), supporting plans for advancement to registrational studies.

Cognition Therapeutics reports positive topline results from its Phase 2 MAGNIFY trial, indicating that zervimesine slowed lesion growth in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Cognition Therapeutics announces its Q1 2025 financial results, highlighting progress in its Alzheimer's disease and dementia with Lewy bodies (DLB) programs, including an FDA meeting request and upcoming presentation of Phase 2 results.

Cognition Therapeutics reports positive Phase 2 results for Zervimesine in Dementia with Lewy Bodies (DLB) and Alzheimer's Disease, shifting focus to late-stage trials and extending cash runway into Q4 2025.

Cognition Therapeutics has been granted an extension by Nasdaq to regain compliance with the minimum bid price requirement, with its stock being transferred to the Nasdaq Capital Market.

Cognition Therapeutics announces positive futility analysis results from its Phase 2 MAGNIFY trial of zervimesine (CT1812) in geographic atrophy, indicating slower lesion growth in treated patients compared to placebo.

Cognition Therapeutics' zervimesine shows promising efficacy and safety in Phase 2 trials for Alzheimer's disease and dementia with Lewy bodies, positioning it as a potential first-to-market treatment for DLB.

Cognition Therapeutics' zervimesine shows promising efficacy and safety results in Phase 2 trials for both Alzheimer's disease and dementia with Lewy bodies, positioning it as a potential first-in-class treatment.

Cognition Therapeutics' Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies showed significant positive signals across multiple symptom domains.

Cognition Therapeutics announced promising results from its Phase 2 SHINE study, showing a significant slowing of cognitive decline in a subgroup of Alzheimer's patients, along with its third quarter 2024 financial results.

Cognition Therapeutics highlights positive Phase 2 results for CT1812 in Alzheimer's disease and expands its clinical program into new indications.

Cognition Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

Cognition Therapeutics highlights positive Phase 2 results for CT1812, an oral drug targeting amyloid oligomers, showing cognitive improvements in Alzheimer's patients and expansion into new indications.